Skip to content

Inventory Market | Monetary Content material Enterprise Web page

The “China Anti-Rheumatic Drug Market – Forecasts from 2022 to 2027” report has been added to’s providing.

China Antirheumatic Medication Market was valued at US$19.081 billion in 2020. The market is projected to develop at a CAGR of three.73% to realize a worth of US$24.654 billion by 2027.

A rising variety of sufferers affected by arthritis in China is the foremost driver of the antirheumatic medication market within the nation. In keeping with the information from the Osteoarthritis Analysis Society Worldwide, its 2018 report confirmed that greater than 8 % of the Chinese language inhabitants resides with physician-diagnosed symptomatic knee OA, whereas the prevalence of any kind of arthritis/rheumatism was round 32.3 %.

As such, altering existence will proceed this development in the course of the subsequent 5 years, thus positively impacting the market progress of antirheumatic medication in China. Excessive R&D investments in creating generic medication are additionally a driving issue for the market progress of antirheumatic medication in China.

The nation is the main exporter of generic medication throughout the globe. With a burgeoning middle-class and rapidly-aging society, China’s pharmaceutical business will proceed to develop in the course of the subsequent 5 years, thereby bolstering the antirheumatic medication market progress.

The current COVID-19 international pandemic outbreak has additionally impacted the expansion of the antirheumatic drug market in China. Pharmaceutical firms are testing current medication that may successfully deal with signs in sufferers contaminated with this novel coronavirus.

In March 2020, China’s Nationwide Well being Fee authorized Roche’s Actemra to deal with critical coronavirus sufferers with lung injury. The drug is often for rheumatoid arthritis, first authorized by the US FDA in 2010. With a steady rise within the variety of COVID-19 sufferers, the demand for this drug is growing, thus positively impacting the market progress.

China’s Antirheumatic Medication market has been segmented primarily based on the kind of illness, kind of molecule, and gross sales channel. By kind of illness, the market has been segmented as osteoarthritis, rheumatoid arthritis, gout, lupus, and others. By kind of molecule, China’s Antirheumatic Medication market has been labeled into prescription drugs and biopharmaceuticals. The market segmentation has additionally been accomplished by gross sales channel as prescription and over-the-counter (OTC).

Key Developments within the Market

In March 2022, Adalimumab biosimilar injection (Junmaikang), co-developed by Shanghai Junshi Biosciences Co. Ltd. and Mabwell Bioscience Co. Ltd., was authorized by the Chinese language Nationwide Medical Merchandise Administration (NMPA). The Nationwide twelfth 5-12 months Plan for Main New Drug Creation Science and Know-how offered important scientific and technological help for the event of Junmaikang, which is used to deal with psoriasis, ankylosing spondylitis, and rheumatoid arthritis.

In March 2022, China’s NMPA authorized using GB242 (infliximab) for the remedy of rheumatoid arthritis, Fistulising Crohn’s illness, and Grownup Ulcerative Colitis, amongst few others. With this approval, Chinese language sufferers may have extra different remedy remedy for the remedy of RA.


COVID-19 had a big influence on China’s antirheumatic medication market. The rising prevalence of rheumatic sufferers led to the elevated demand for medication within the nation.

Nevertheless, the mandated lockdown and social distancing measures resulted within the closure of many manufacturing amenities and low staffing, slowing down productiveness. The journey restrictions additionally affected the imports and exports in China, creating a spot within the provide and demand chain. The explanations talked about above slowed down the market’s progress.

Key Subjects Coated:


1.1. Market Overview

1.2. COVID-19 Influence

1.3. Market Definition

1.4. Market Segmentation

2.Analysis Methodology

2.1. analysis knowledge

2.2. assumptions

3.Government Abstract

3.1. Analysis Highlights

4.Market Dynamics

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s 5 Forces Evaluation

4.4. Trade Worth Chain Evaluation

5. China Antirheumatic Medication Market Evaluation, By Sort of Illness

5.1. Introduction

5.2. osteoarthritis

5.3. Rheumatoid Arthritis

5.4. gout

5.5. Lupus

5.6. others

6. China Antirheumatic Medication Market Evaluation, By Sort of Molecule

6.1. Introduction

6.2. Prescribed drugs

6.3. Biopharmaceuticals

7. China Antirheumatic Medication Market Evaluation, By Gross sales Channel

7.1. Introduction

7.2. prescription

7.3. Over-The-Counter (OTC)

8. Aggressive Setting and Evaluation

8.1. Main Gamers and Technique Evaluation

8.2. Rising Gamers and Market Lucrativeness

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Vendor Competitiveness Matrix

9.Firm Profiles

9.1. Pfizer Inc.

9.2. F. Hoffmann-La Roche Ltd

9.3. UCB SA

9.4. Eli Lilly and Firm

9.5. AbbVie Inc.

For extra details about this report go to is the world’s main supply for worldwide market analysis stories and market knowledge. We offer you the most recent knowledge on worldwide and regional markets, key industries, the highest firms, new merchandise and the most recent tendencies.

Leave a Reply

Your email address will not be published. Required fields are marked *